ERBB2 and breast carcinoma: Combinations of metformin and breast cancer drugs, such as trastuzumab, have shown particular efficacy in increasing disease-free and overall survival in diabetic patients with early-stage HER2+ breast cancer in a phase III clinical study [160], suggesting that metformin improves antitumor therapy in breast cancer.